Google Ads healthcare policy and LegitScript — the 2026 deep guide
A working reference for growth leads, agency account managers, and Compliance Officers who own paid-search performance for US healthcare accounts. Written against the current Google Ads healthcare and medicines policy, the LegitScript public program materials for addiction treatment, online pharmacy, cell/gene therapy and hormone therapy, and the disapproval-appeal workflow that keeps regulated accounts live.
- Google Ads restricts advertising for online pharmacies, addiction treatment services, cell and gene therapy providers, and hormone-therapy telemedicine providers targeting US audiences. Each of these requires LegitScript certification plus an in-platform certifier ID before ads serve.
- General clinical services (dental, aesthetic, primary care, cardiology, orthopaedics and most specialty medicine) do not need LegitScript. They still sit inside the healthcare-and-medicines policy and state-medical-board advertising rules.
- Prescription-drug advertising to US audiences requires additional disclosures — including the FDA-mandated safety information and links to full prescribing information for branded ads.
- Disapprovals in regulated verticals fall into a small number of repeating buckets: unapproved terms, missing certifier IDs, destination URL redirects, and before-and-after imagery. Each has a documented fix pattern.
- The safe-launch architecture for a restricted vertical is: LegitScript certified first, certifier ID linked in Google Ads, landing pages audited for prohibited terms and imagery, prescription disclosures compliant, and a documented HIPAA-safe conversion pipeline in place before spend begins.
- The Google Ads healthcare policy map
- LegitScript scope — which verticals actually need it
- Online pharmacies — the LegitScript pharmacy programme
- Addiction treatment — the highest-scrutiny vertical
- Cell and gene therapy — the newer restricted category
- Hormone-therapy telemedicine — the 2022 expansion
- Disapproval recovery patterns
- FAQ
-
Primary Care · North Dallas, TXCase study →
-
MedSpa · North Dallas, TX
-
Skin Care · Beverly Hills, CA
-
Dental · Christiansburg, VACase study →
-
Pediatrics · Blacksburg, VACase study →
-
Pediatric Dentistry · Blacksburg, VACase study →
-
Dental · Roanoke, VACase study →
-
Functional Medicine · Telehealth · USACase study →
“They were able to get all my ideas and work with me over a period of three to four months and create this amazing website. It's super customized, very modern, and it incorporates all the elements that I had wanted — the patient portal, nice pictures, a very interactive website, patient reviews. I would highly recommend their company to anyone who wants to make an excellent website.”
The Google Ads healthcare policy map
Google Ads publishes its Healthcare and Medicines policy as a single umbrella framework with vertical-specific sub-sections. The three practical dimensions for a US advertiser are the country of the audience, the type of service or product being advertised, and whether the destination URL contains regulated content. All three combine to decide whether an ad serves, is disapproved, or requires a certifier ID.
The umbrella policy names three categories of content: restricted (may run only if additional conditions are met — often a certifier ID and geographic gating), prohibited (never runs — unapproved substances, illegal pharmaceuticals, and pharmacy operations without the required credentials), and disclosure-conditional (may run if specific on-ad or on-landing-page disclosures are visible — for example FDA-mandated safety information on branded prescription-drug ads).
The four gates every regulated healthcare ad must pass
Every ad in a regulated vertical passes through four independent gates before it serves. First, the account itself must be authorised to serve the vertical, which for restricted categories means a certifier ID on file inside the Google Ads account. Second, the ad copy must clear automated policy screening for prohibited terms and language patterns. Third, the destination URL must be a certified endpoint that does not redirect to non-certified content. Fourth, the landing page must contain the mandated disclosures for its category.
Skipping any one of these results in an ad disapproval; skipping two or more can result in an account-level restriction that requires manual review to lift. The four-gate model is why "our ad got disapproved" is never enough diagnostic detail — the fix depends on which gate failed.
How the policy interacts with state medical boards
Google Ads policy is layered on top of state-medical-board advertising rules, which are stricter in some states than the platform baseline. Texas Medical Board Rule 164, California Business and Professions Code 651, and Florida Board of Medicine Rule 64B8 all impose testimonial, before-and-after and endorsement rules that a Google Ads ad must respect in addition to the platform policy. When they conflict, the stricter rule always wins.
LegitScript scope — which verticals actually need it
LegitScript operates as Google's designated third-party certifier for a defined set of restricted healthcare verticals. A LegitScript certification is not a Google product — it is an independent programme with its own audit criteria, fees and monitoring — but Google Ads has adopted it as the qualifying credential for four US healthcare verticals as of 2026.
- Online pharmacies operating in the United States that dispense prescription drugs, including telepharmacy models and mail-order pharmacies.
- Addiction treatment services in the United States — inpatient rehabilitation, outpatient programmes, medication-assisted treatment providers, sober-living residences and detox services.
- Cell and gene therapy providers in the United States — advertising or promoting cellular products including stem-cell interventions.
- Hormone-therapy telemedicine providers targeting US audiences — testosterone, HRT, peptides and other hormone-adjacent categories added in the 2022 policy expansion.
Certification is annual. The LegitScript ID must be added inside the Google Ads account under the certifier ID field before ads in the vertical will serve. If the certification lapses, ads stop serving on the renewal deadline whether or not the renewal application is in progress.
Verticals that do not need LegitScript
The LegitScript gate is narrow. Dental practices, aesthetic and medspa clinics, primary-care groups, specialty-medicine groups, urgent care, physiotherapy and orthopaedic clinics do not need LegitScript to advertise on Google Ads. They sit inside the general healthcare-and-medicines policy and the applicable state-medical-board rules. Adding a LegitScript certification to one of these verticals is not required and does not confer any policy advantage inside Google Ads.
Online pharmacies — the LegitScript pharmacy programme
The LegitScript online-pharmacy programme evaluates operational integrity, licensure, prescription-verification workflow, patient-safety measures and pharmacist supervision. A US pharmacy applicant must be licensed in every state to which it dispenses, hold the applicable federal registrations (DEA where controlled substances are involved), and demonstrate a valid prescription-verification pathway before dispensing.
Multi-state mail-order pharmacies typically undergo the most extensive review because each state licensure must be verified. Applications with lapsed or reciprocity-based licences are the most common cause of extended review timelines.
Ad copy and landing page requirements for pharmacies
- Ad copy must not reference specific prescription-drug names in a way that violates FDA promotional rules. Branded prescription-drug ads must carry the required safety information and links to full prescribing information.
- Landing pages must display the pharmacy's state licence numbers, physical dispensing address, and pharmacist-in-charge contact detail in a visible location.
- Any "no prescription needed" language, coupon aggregators for controlled substances, or unapproved-drug promotions are prohibited across both ad and landing page.
- Destination URLs must go directly to certified endpoints. Redirects through non-certified affiliate networks are a common disapproval cause and, in some cases, an account-suspension cause.
Federal law layering — the Ryan Haight Act
Online-pharmacy advertising must also respect the Ryan Haight Online Pharmacy Consumer Protection Act (21 USC 829(e)), which requires at least one in-person medical evaluation before a controlled substance may be prescribed via the internet, subject to defined telemedicine exceptions. Google Ads policy references this framework indirectly by prohibiting ads that facilitate a workflow inconsistent with it.
Addiction treatment — the highest-scrutiny vertical
Google Ads first paused advertising in the US addiction-treatment vertical in 2017, then reopened it under the LegitScript addiction-treatment certification programme. The programme was designed to filter out patient-brokering and referral-fee arrangements — the practices that had triggered the pause — and it remains the strictest LegitScript vertical.
A US treatment-provider applicant must operate a physical facility, hold the applicable state licensure, meet the LegitScript standards for admissions transparency and continuity-of-care documentation, and demonstrate that its marketing arrangements do not include patient-brokering. The 2018 EKRA statute (Eliminating Kickbacks in Recovery Act, 18 USC 220) codified the federal prohibition on patient-brokering in the treatment vertical and is directly relevant to any performance-based marketing arrangement.
What EKRA changes for marketing operations
EKRA prohibits knowingly and wilfully soliciting, receiving, paying or offering any remuneration (including a kickback, bribe or rebate) directly or indirectly, overtly or covertly, in return for referring a patient or in exchange for an individual using the services of a recovery home, clinical treatment facility, or laboratory. Unlike the federal Anti-Kickback Statute, EKRA applies to all payors — commercial insurance and cash-pay included — not just federal healthcare programmes.
The practical implication for marketing operations is that pay-per-admission arrangements with call-centre vendors, per-lead payment models tied to admitted patients, and volume-based bonuses on marketing contracts all sit inside EKRA's zone of concern. The 2018 statute has a narrow safe harbour for W-2 employees paid a bona fide salary, and DOJ has brought enforcement actions against non-conforming arrangements.
Ad copy and landing page requirements for addiction treatment
- Ad copy must not imply guaranteed outcomes or "we can get you insurance to cover" language. Both are documented disapproval triggers and enforcement themes.
- Landing pages must display the licensed operating name, licence numbers, physical addresses of dispensing facilities, and a clear description of medically supervised versus non-medical services.
- Testimonials, if used at all, must comply with the FTC Endorsement Guides — which for recovery-related testimonials require disclosure of any material connection between the endorser and the provider.
- Before-and-after imagery is not permitted. Any imagery implying a specific treatment outcome is a common disapproval and a source of state-medical-board complaints in this vertical.
Cell and gene therapy — the newer restricted category
Google Ads added cell and gene therapy providers to the LegitScript-certified restricted category in the 2022 policy expansion. The category covers advertising by clinics and providers for cellular products — including autologous and allogeneic stem-cell interventions, exosome-based therapies, platelet-rich plasma outside standard orthopaedic use cases, and gene-therapy products — targeted at US audiences.
The category exists because the FDA had been signalling growing concern about unapproved cellular products being marketed direct-to-consumer for indications not supported by cleared or approved evidence. The United States v. US Stem Cell injunction in 2019, followed by increased FDA enforcement letters, moved the market toward tighter platform gating.
The FDA framework and how it maps to ad policy
The FDA regulates cellular and gene-therapy products under 21 CFR 1271. Products that meet the "minimal manipulation" and "homologous use" criteria may qualify as Section 361 products; those that do not are Section 351 biologics requiring an approved Biologics License Application or an Investigational New Drug application. A clinic advertising cellular products for indications outside the Section 361 carve-out is advertising a product that would require an approved BLA — and Google Ads policy treats this as a prohibited-content pattern regardless of LegitScript status.
Practical implication: LegitScript certification for cell and gene therapy is not a shortcut around FDA framework. It is a signal that the operator has been reviewed against a defined set of criteria. The ad must still respect the boundaries of FDA-cleared indications for the specific product being advertised.
Hormone-therapy telemedicine — the 2022 expansion
Google Ads added hormone-therapy telemedicine providers to the LegitScript restricted list in the 2022 policy update. The category covers online-first providers dispensing or prescribing testosterone, estrogen and other regulated hormones through a telemedicine intake model, and peptide providers that fall inside the DEA controlled-substance framework.
The certification review here focuses heavily on the medical-evaluation pathway. A compliant telemedicine hormone provider must document a bona fide provider-patient relationship, a valid clinical evaluation before prescribing, appropriate laboratory testing, an ongoing monitoring protocol, and — where controlled substances are dispensed — an in-person evaluation that satisfies the Ryan Haight Act or a qualifying telemedicine registration.
Ad copy and imagery constraints for hormone telemedicine
- Testosterone replacement therapy ads must not target audiences primarily on the basis of a specific health condition inferred by the platform. The Google Ads sensitive-interest-categories policy applies.
- Anti-ageing and performance-enhancement framing is a documented disapproval theme. Ads must anchor to a legitimate medical indication with an evidence-supported dosage pathway.
- Before-and-after physique imagery is prohibited across all restricted-hormone categories.
- Landing pages must disclose the medical-evaluation workflow, the physicians licensed in the relevant states, and the pharmacy or dispensing partner that fulfils the prescription.
The disapproval-recovery playbook
1. Diagnose the gate that failed
Read the specific disapproval reason in the account. Match to the four-gate model (authorisation, ad copy, destination URL, landing-page disclosure). Fix the gate that failed, not the ad.
2. Audit the destination URL chain
Follow every redirect from ad-click to final landing page. Any hop through a non-certified domain is disqualifying in a restricted vertical. Rebuild the chain to a first-party, certified endpoint.
3. Rebuild ad copy against the term-block list
Maintain an internal block-list of terms that trigger automated policy screening in the vertical. Rewrite ad copy against the block-list before resubmission. Track disapproval rate as a quality metric.
4. Escalate through the specialist support path
For account-level restrictions, escalate through the healthcare-specialist support queue rather than standard policy appeals. Provide the LegitScript ID, physical operating detail, and the corrective action taken.
5. Document the fix inside the CAP
If the practice operates under a corrective-action plan (CAP) with a state medical board or LegitScript, log every disapproval and fix inside the CAP timeline. Documented remediation is what closes CAP items on time.
6. Build a pre-submission review workflow
Route every ad through internal policy review before it reaches the Google Ads submission queue. A pre-submission checklist against the four gates reduces disapproval rate by 60 to 80 percent in the accounts we've operated.
Prescription-drug ad disclosures — the FDA layer
Beyond LegitScript and the platform policy sits the FDA framework for prescription-drug advertising. Direct-to-consumer prescription-drug ads are regulated under 21 CFR 202.1, which requires fair balance — a presentation of both benefits and risks — and disclosure of major side effects, contraindications and effectiveness. Branded prescription-drug ads must carry the "important safety information" summary or link to the full prescribing information.
For a search ad, the FDA's guidance on internet advertising treats the ad and the landing page together — an ad with a branded drug name and a claimed benefit must lead to a landing page that presents the fair-balance material. Reminder ads (brand-only, no indication or benefit claim) and help-seeking ads (indication-only, no brand) have separate rules and can serve without full fair balance, but they may not combine both elements in the same asset.
How Ichelon Consulting US operates a restricted-vertical Google Ads account
A restricted-vertical account is a different operating rhythm from a general clinical account. The daily flow has three layers: policy screening at submission, disapproval triage at 24-hour intervals, and monthly certifier-status review. We staff each layer with a named owner inside the account team and audit the flow monthly against the LegitScript renewal checklist.
- Account architecture. Certified endpoint is a first-party subdomain. Ad copy library maintained in a governed asset system. Landing-page templates versioned in review-cycle sprints.
- HIPAA-safe conversion pipeline. Server-side event forwarding with field-level scrubbing before any event reaches Google Ads. No condition-URL forwarding, no authenticated-page tags.
- Reporting rhythm. Weekly disapproval-rate dashboards. Monthly LegitScript-monitoring status. Quarterly compliance review against the state-medical-board framework applicable to the operating states.
- Reviewer discipline. Every ad and landing page reviewed against the four gates by a paid-media compliance reviewer before submission.
Google Ads healthcare policy — common questions
Which healthcare verticals need LegitScript certification to run Google Ads?
Online pharmacies, addiction treatment services, cell and gene therapy providers, and hormone-therapy telemedicine providers targeting US audiences. Each of these requires a LegitScript certification plus an in-platform certifier ID before ads serve.
How long does LegitScript certification take?
Standard timelines are 45 to 90 days for a straightforward application and 90 to 150 days when supplemental documentation is requested. Renewal is a shorter cycle, generally 30 to 60 days, and must complete before expiry to avoid a certification lapse.
What are the current LegitScript certification fees?
Public application fees range from about USD 1,995 for a single addiction-treatment location up to several thousand USD for multi-location pharmacy applications, plus annual monitoring. LegitScript publishes the current schedule on its own site — costs quoted here are directional.
Can we advertise a general clinical service on Google Ads without LegitScript?
Yes. Dental, aesthetic, primary-care and most specialty medicine can advertise without LegitScript, subject to the general healthcare policy, state-medical-board rules, and disclosure requirements for prescription-drug ads.
What triggers a healthcare-policy disapproval?
Unapproved-substance keywords in ad copy or landing pages, prescription-drug pricing without required disclaimers, before-and-after imagery in restricted regions, missing certifier IDs for regulated verticals, and destination URLs that redirect to non-certified endpoints.
Is this guide legal advice?
No. This is marketing best practice reviewed against current Google Ads policy documentation and LegitScript public program materials. Consult a healthcare-marketing attorney and, for prescription-drug advertising, FDA-experienced counsel before publishing.
Scope your restricted-vertical Google Ads engagement
Book a 30-minute call with a member of the Leadership Team, email the US practice lead, or WhatsApp us in your time zone. Retainers are custom-scoped per engagement · from USD ~$250/month equivalent (approx Rs 20,000).